IMMNOV — Immunovia AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK84.33m
- SEK41.94m
- SEK1.58m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.356 | 0.362 | 0.844 | 1.15 | 1.57 |
Cost of Revenue | |||||
Gross Profit | -51.2 | -50.8 | -66.8 | -80.8 | -73.8 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 115 | 135 | 167 | 192 | 298 |
Operating Profit | -114 | -134 | -167 | -191 | -296 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -115 | -146 | -156 | -168 | -309 |
Provision for Income Taxes | |||||
Net Income After Taxes | -115 | -146 | -156 | -168 | -309 |
Net Income Before Extraordinary Items | |||||
Net Income | -115 | -146 | -156 | -168 | -309 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -115 | -146 | -156 | -168 | -309 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.43 | -6.35 | -6.4 | -6.89 | -4.75 |
Dividends per Share |